Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease

被引：30
作者：
Hindryckx, Pieter [1 ]
Novak, Gregor [2 ]
Bonovas, Stefanos [3 ]
Peyrin-Biroulet, Laurent [4 ]
Danese, Silvio [3 ,5 ]
机构：
[1] Univ Ghent, Dept Gastroenterol, Ghent, Belgium
[2] Univ Ljubljana, Dept Gastroenterol, Med Ctr, Ljubljana, Slovenia
[3] Humanitas Clin & Res Ctr, IBD Ctr, Dept Gastroenterol, Milan, Italy
[4] Lorraine Univ, Univ Hosp Nancy, Inserm, U954, Vandoeuvre Les Nancy, France
[5] Humanitas Univ, Dept Biomed Sci, Milan, Italy
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 04期
关键词：
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EVENT TRIAL TARGET; CARDIOVASCULAR SAFETY; CENTRAL SENSITIZATION; CHRONIC PAIN; CYCLOOXYGENASE ISOFORMS; OSTEOARTHRITIS PAIN; ARTHRITIS RESEARCH; KNEE REPLACEMENT; COX-2; INHIBITION;
D O I：
10.1002/cpt.791
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).
引用
收藏
页码：633 / 641
页数：9
相关论文
共 101 条
[41]   Evidence of augmented central pain processing in idiopathic chronic low back pain [J].
Giesecke, T ;
Gracely, RH ;
Grant, MAB ;
Nachemson, A ;
Petzke, F ;
Williams, DA ;
Clauw, DJ .
ARTHRITIS AND RHEUMATISM, 2004, 50 (02) :613-623
[42]   Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use [J].
Gorski, T. ;
Cadore, E. Lusa ;
Pinto, S. Santana ;
da Silva, E. Marczwski ;
Correa, C. Silva ;
Beltrami, F. Gabe ;
Martins Kruel, L. F. .
BRITISH JOURNAL OF SPORTS MEDICINE, 2011, 45 (02) :85-90
[43]   Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities [J].
Grosser, T ;
Fries, S ;
FitzGerald, GA .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :4-15
[44]   The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs [J].
Grosser, Tilo ;
Ricciotti, Emanuela ;
FitzGerald, Garret A. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2017, 38 (08) :733-748
[45]   Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis [J].
Grosser, Tilo .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1389-1389
[46]   Time for nonaddictive relief of pain [J].
Grosser, Tilo ;
Woolf, Clifford J. ;
FitzGerald, Garret A. .
SCIENCE, 2017, 355 (6329) :1026-1027
[47]   Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga [J].
Grosser, Tilo ;
Yu, Ying ;
FitzGerald, Garret A. .
ANNUAL REVIEW OF MEDICINE, 2010, 61 :17-33
[48]   GlyR α3:: An essential target for spinal PGE2-mediated inflammatory pain sensitization [J].
Harvey, RJ ;
Depner, UB ;
Wässle, H ;
Ahmadi, S ;
Heindl, C ;
Reinold, H ;
Smart, TG ;
Harvey, K ;
Schütz, B ;
Abo-Salem, OM ;
Zimmer, A ;
Poisbeau, P ;
Welzl, H ;
Wolfer, DP ;
Betz, H ;
Zeilhofer, HU ;
Müller, U .
SCIENCE, 2004, 304 (5672) :884-887
[49]   Measures of Adult Pain Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP) [J].
Hawker, Gillian A. ;
Mian, Samra ;
Kendzerska, Tetyana ;
French, Melissa .
ARTHRITIS CARE & RESEARCH, 2011, 63 :S240-S252
[50]   Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation [J].
Hermanson, Daniel J. ;
Hartley, Nolan D. ;
Gamble-George, Joyonna ;
Brown, Naoko ;
Shonesy, Brian C. ;
Kingsley, Phillip J. ;
Colbran, Roger J. ;
Reese, Jeffrey ;
Marnett, Lawrence J. ;
Patel, Sachin .
NATURE NEUROSCIENCE, 2013, 16 (09) :1291-U176
12345678910